JPWO2020022363A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020022363A5 JPWO2020022363A5 JP2020532431A JP2020532431A JPWO2020022363A5 JP WO2020022363 A5 JPWO2020022363 A5 JP WO2020022363A5 JP 2020532431 A JP2020532431 A JP 2020532431A JP 2020532431 A JP2020532431 A JP 2020532431A JP WO2020022363 A5 JPWO2020022363 A5 JP WO2020022363A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- production method
- buffer
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024009164A JP7674542B2 (ja) | 2018-07-25 | 2024-01-25 | 抗体－薬物コンジュゲートの効果的な製造方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018139633 | 2018-07-25 | ||
| JP2018139633 | 2018-07-25 | ||
| PCT/JP2019/028949 WO2020022363A1 (ja) | 2018-07-25 | 2019-07-24 | 抗体－薬物コンジュゲートの効果的な製造方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024009164A Division JP7674542B2 (ja) | 2018-07-25 | 2024-01-25 | 抗体－薬物コンジュゲートの効果的な製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2020022363A1 JPWO2020022363A1 (ja) | 2021-08-02 |
| JPWO2020022363A5 true JPWO2020022363A5 (https=) | 2022-08-01 |
Family
ID=69181569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532431A Ceased JPWO2020022363A1 (ja) | 2018-07-25 | 2019-07-24 | 抗体−薬物コンジュゲートの効果的な製造方法 |
| JP2024009164A Active JP7674542B2 (ja) | 2018-07-25 | 2024-01-25 | 抗体－薬物コンジュゲートの効果的な製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024009164A Active JP7674542B2 (ja) | 2018-07-25 | 2024-01-25 | 抗体－薬物コンジュゲートの効果的な製造方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210283269A1 (https=) |
| EP (1) | EP3828206A4 (https=) |
| JP (2) | JPWO2020022363A1 (https=) |
| KR (1) | KR20210038904A (https=) |
| CN (1) | CN112566942A (https=) |
| AU (1) | AU2019311557A1 (https=) |
| BR (1) | BR112021001194A2 (https=) |
| CA (1) | CA3107417C (https=) |
| IL (1) | IL280295B2 (https=) |
| SG (1) | SG11202100653YA (https=) |
| TW (2) | TWI847992B (https=) |
| WO (1) | WO2020022363A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018320470B2 (en) * | 2017-08-23 | 2025-04-24 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
| CN115103858B (zh) * | 2020-03-25 | 2025-07-15 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| IL299803A (en) * | 2020-07-17 | 2023-03-01 | Daiichi Sankyo Co Ltd | Production method for antibody-drug conjugate |
| JP7848119B2 (ja) * | 2020-07-20 | 2026-04-20 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ |
| JP2023545096A (ja) * | 2020-10-09 | 2023-10-26 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲート及びｐａｒｐ１選択的阻害薬の組み合わせ |
| AU2021378152A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY |
| CN116583526B (zh) * | 2020-12-11 | 2025-09-26 | 微境生物医药科技(上海)有限公司 | 新型喜树碱衍生物、含其的组合物和其用途 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| MX2024003277A (es) * | 2021-09-15 | 2024-04-04 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia. |
| KR20240099178A9 (ko) | 2021-10-18 | 2025-12-10 | 다이이찌 산쿄 가부시키가이샤 | 항 cd37 항체-약물 콘주게이트 |
| AU2022389555A1 (en) * | 2021-11-17 | 2024-07-04 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate and use thereof |
| EP4514391A1 (en) * | 2022-04-27 | 2025-03-05 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
| CN119255825A (zh) * | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| AU2023328010A1 (en) * | 2022-08-25 | 2025-03-20 | Genequantum Healthcare (Suzhou) Co., Ltd. | Pharmaceutical composition of antibody drug conjugate |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| AU2024264024A1 (en) * | 2023-04-23 | 2025-11-06 | CSPC Megalith Biopharmaceutical Co., Ltd. | Use of antibody drug conjugate |
| AU2024273972A1 (en) * | 2023-05-16 | 2025-12-04 | CSPC Megalith Biopharmaceutical Co., Ltd. | Pharmaceutical composition comprising antibody-drug conjugate |
| EP4737483A1 (en) | 2023-06-30 | 2026-05-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate production method including purification step using activated carbon material |
| WO2025021118A1 (zh) * | 2023-07-25 | 2025-01-30 | 海南先声再明医药股份有限公司 | 配体-药物偶联物及其偶联连接子 |
| WO2025054996A1 (en) * | 2023-09-15 | 2025-03-20 | Duality Biologics (Suzhou) Co., Ltd. | Antibody-drug conjugate |
| CN121969401A (zh) * | 2023-09-26 | 2026-05-01 | 信达生物制药(苏州)有限公司 | 靶向her3的抗体-药物偶联物 |
| WO2025260285A1 (en) * | 2024-06-19 | 2025-12-26 | Duality Biologics (Suzhou) Co., Ltd. | Antibody drug conjugate |
| WO2025262130A1 (en) * | 2024-06-19 | 2025-12-26 | BioNTech SE | Antibody drug conjugate |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| ES2503719T3 (es) | 2005-02-11 | 2014-10-07 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpos y de maitansinoides |
| CA3000520C (en) | 2005-08-24 | 2023-04-04 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| JP4861019B2 (ja) * | 2006-01-31 | 2012-01-25 | 独立行政法人科学技術振興機構 | ヒトＴＮＦ−αに対する抗体酵素およびその利用 |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| ES2813398T3 (es) * | 2009-10-20 | 2021-03-23 | Abbvie Inc | Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A |
| MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| DK2934582T3 (da) * | 2012-12-21 | 2020-02-24 | Ichnos Sciences SA | Anti-her2-antistofformulering |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| RU2680404C2 (ru) | 2014-01-10 | 2019-02-21 | Синтон Байофармасьютикалс Б. В. | Способ очистки cys-связанных конъюгатов антитело-лекарственное средство |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| CN106999606B (zh) * | 2015-02-17 | 2020-06-19 | 上海美雅珂生物技术有限责任公司 | 抗体药物偶联物 |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| KR20190066026A (ko) * | 2016-10-07 | 2019-06-12 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료 |
| JP6679762B2 (ja) | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
-
2019
- 2019-07-24 SG SG11202100653YA patent/SG11202100653YA/en unknown
- 2019-07-24 AU AU2019311557A patent/AU2019311557A1/en active Pending
- 2019-07-24 CN CN201980049551.8A patent/CN112566942A/zh active Pending
- 2019-07-24 IL IL280295A patent/IL280295B2/en unknown
- 2019-07-24 CA CA3107417A patent/CA3107417C/en active Active
- 2019-07-24 EP EP19842020.0A patent/EP3828206A4/en active Pending
- 2019-07-24 BR BR112021001194-3A patent/BR112021001194A2/pt unknown
- 2019-07-24 KR KR1020217005281A patent/KR20210038904A/ko not_active Ceased
- 2019-07-24 US US17/262,590 patent/US20210283269A1/en active Pending
- 2019-07-24 TW TW108126115A patent/TWI847992B/zh active
- 2019-07-24 JP JP2020532431A patent/JPWO2020022363A1/ja not_active Ceased
- 2019-07-24 WO PCT/JP2019/028949 patent/WO2020022363A1/ja not_active Ceased
- 2019-07-24 TW TW113105008A patent/TWI865337B/zh active
-
2024
- 2024-01-25 JP JP2024009164A patent/JP7674542B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020022363A5 (https=) | ||
| JP7708133B2 (ja) | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | |
| CN113227124B (zh) | 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐 | |
| KR102880460B1 (ko) | 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염 | |
| US20170184580A1 (en) | Bis-biotinylation tags | |
| JP2009509535A5 (https=) | ||
| SI2238172T1 (en) | A composition comprising an antibody that binds to the II HER2 domain and its acidic variant | |
| GB1571993A (en) | Process for producing insoluble solid supports | |
| JP2016512848A (ja) | 抗体の精製及び純度のモニタリング | |
| EA011168B1 (ru) | Способ очистки конъюгатов альбумина | |
| KR20150118103A (ko) | 단백질 정제 방법 | |
| JP2022524338A5 (https=) | ||
| TWI325430B (en) | Aminated complex type sugar chain derivative and its production method | |
| US20220144883A1 (en) | Methods of modifying phosphorylated or sulfated tyrosine residues of polypeptides | |
| AU2022208654B2 (en) | Compound or salt thereof, and antibody produced using same | |
| WO2004090542A1 (ja) | タンパク質アレイ及びその作製方法 | |
| CN118290513B (zh) | 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物 | |
| EP4114865B1 (en) | Protease-processed molecules | |
| EP0991944A1 (en) | Methods for covalent immobilisation of biomolecules to a carrier by means of a his-tag | |
| JP2023526450A5 (https=) | ||
| CN112898172B (zh) | 可被羧肽酶酶解的双亲和功能团化合物的合成方法 | |
| JP6325544B2 (ja) | 原核細胞のペリプラズムにおけるポリペプチドの産生のための方法 | |
| US20230382946A1 (en) | Polypeptide or protein directional modification method based on sulfhydryl-alkenyl azide coupling | |
| RU2846294C1 (ru) | Молекулы, получаемые посредством процессинга протеазами | |
| CA2371222C (fr) | Support solide fonctionnalise pour la synthese d'alpha-oxoaldehydes |